Topical Collection "Ocean4Biotech"

Editors

Dr. Ana Rotter
E-Mail Website
Collection Editor
Marine Biology Station Piran, National Institute of Biology, Slovenia
Dr. Susana P Gaudencio
E-Mail Website
Collection Editor
UCIBIO – Applied Biomolecular Sciences Unit, Chemistry Department, Blue Biotechnology and Biomedicine Lab, Nova School of Science and Technology, Nova University of Lisbon, Lisbon, Portugal
Interests: marine natural products; structure elucidation; secondary metabolites; blue biotechnology; bioactive compounds from actinomycetes; drug discovery and biotechnological applications
Special Issues, Collections and Topics in MDPI journals
Dr. Katja Klun
E-Mail Website
Collection Editor
Marine Biology Station Piran, National Institute of Biology, Slovenia
Dr. Marlen I. Vasquez
E-Mail
Collection Editor
Department of Chemical Engineering, Cyprus University of Technology, Cyprus

Topical Collection Information

Dear Colleagues,

Oceans will be our most valuable source of new products (from novel drugs to innovative biomaterials) to help us overcome societal challenges. Technology is advancing at an unprecedented pace, providing us with the tools necessary to answer important chemical and biological questions and promote scientific discoveries. Moreover, it is irrefutable that science and innovation, from basic research to applied sciences, must be performed in transdisciplinary groups. Ocean4Biotech—a European transdisciplinary networking platform for marine biotechnology—is a European-Commission-funded COST Action that aims to bring together multiple disciplines and include all relevant experts from marine-biotechnology-related fields. This Special Issue is open to all individual experts and researchers connected with Ocean4Biotech, relating to sampling methods, the discovery of natural marine products, process optimization, and use case scenarios. We believe that the research outputs that will be presented in this Special Issue will significantly benefit the global marine biotechnology sector and will place participants on the global map of marine biotechnology knowledge providers.

Dr. Ana Rotter
Dr. Susana P Gaudencio
Dr. Katja Klun
Dr. Marlen I. Vasquez
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (3 papers)

2022

Jump to: 2021, 2020

Perspective
Responsible Research and Innovation Framework, the Nagoya Protocol and Other European Blue Biotechnology Strategies and Regulations: Gaps Analysis and Recommendations for Increased Knowledge in the Marine Biotechnology Community
Mar. Drugs 2022, 20(5), 290; https://doi.org/10.3390/md20050290 - 26 Apr 2022
Viewed by 1415
Abstract
As the quest for marine-derived compounds with pharmacological and biotechnological potential upsurges, the importance of following regulations and applying Responsible Research and Innovation (RRI) also increases. This article aims at: (1) presenting an overview of regulations and policies at the international and EU [...] Read more.
As the quest for marine-derived compounds with pharmacological and biotechnological potential upsurges, the importance of following regulations and applying Responsible Research and Innovation (RRI) also increases. This article aims at: (1) presenting an overview of regulations and policies at the international and EU level, while demonstrating a variability in their implementation; (2) highlighting the importance of RRI in biodiscovery; and (3) identifying gaps and providing recommendations on how to improve the market acceptability and compliance of novel Blue Biotechnology compounds. This article is the result of the work of the Working Group 4 “Legal aspects, IPR and Ethics” of the COST Action CA18238 Ocean4Biotech, a network of more than 130 Marine Biotechnology scientists and practitioners from 37 countries. Three qualitative surveys (“Understanding of the Responsible Research and Innovation concept”, “Application of the Nagoya Protocol in Your Research”, and “Brief Survey about the experiences regarding the Nagoya Protocol”) indicate awareness and application gaps of RRI, the Nagoya Protocol, and the current status of EU policies relating to Blue Biotechnology. The article categorises the identified gaps into five main categories (awareness, understanding, education, implementation, and enforcement of the Nagoya Protocol) and provides recommendations for mitigating them at the European, national, and organisational level. Full article
Show Figures

Graphical abstract

2021

Jump to: 2022, 2020

Article
The Diversity, Metabolomics Profiling, and the Pharmacological Potential of Actinomycetes Isolated from the Estremadura Spur Pockmarks (Portugal)
Mar. Drugs 2022, 20(1), 21; https://doi.org/10.3390/md20010021 - 23 Dec 2021
Cited by 1 | Viewed by 1541
Abstract
The Estremadura Spur pockmarks are a unique and unexplored ecosystem located in the North Atlantic, off the coast of Portugal. A total of 85 marine-derived actinomycetes were isolated and cultured from sediments collected from this ecosystem at a depth of 200 to 350 [...] Read more.
The Estremadura Spur pockmarks are a unique and unexplored ecosystem located in the North Atlantic, off the coast of Portugal. A total of 85 marine-derived actinomycetes were isolated and cultured from sediments collected from this ecosystem at a depth of 200 to 350 m. Nine genera, Streptomyces, Micromonospora, Saccharopolyspora, Actinomadura, Actinopolymorpha, Nocardiopsis, Saccharomonospora, Stackebrandtia, and Verrucosispora were identified by 16S rRNA gene sequencing analyses, from which the first two were the most predominant. Non-targeted LC-MS/MS, in combination with molecular networking, revealed high metabolite diversity, including several known metabolites, such as surugamide, antimycin, etamycin, physostigmine, desferrioxamine, ikarugamycin, piericidine, and rakicidin derivatives, as well as numerous unidentified metabolites. Taxonomy was the strongest parameter influencing the metabolite production, highlighting the different biosynthetic potentials of phylogenetically related actinomycetes; the majority of the chemical classes can be used as chemotaxonomic markers, as the metabolite distribution was mostly genera-specific. The EtOAc extracts of the actinomycete isolates demonstrated antimicrobial and antioxidant activity. Altogether, this study demonstrates that the Estremadura Spur is a source of actinomycetes with potential applications for biotechnology. It highlights the importance of investigating actinomycetes from unique ecosystems, such as pockmarks, as the metabolite production reflects their adaptation to this habitat. Full article
Show Figures

Figure 1

2020

Jump to: 2022, 2021

Review
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes
Mar. Drugs 2020, 18(12), 619; https://doi.org/10.3390/md18120619 - 04 Dec 2020
Cited by 27 | Viewed by 4211
Abstract
The marine environment is a rich source of biologically active molecules for the treatment of human diseases, especially cancer. The adaptation to unique environmental conditions led marine organisms to evolve different pathways than their terrestrial counterparts, thus producing unique chemicals with a broad [...] Read more.
The marine environment is a rich source of biologically active molecules for the treatment of human diseases, especially cancer. The adaptation to unique environmental conditions led marine organisms to evolve different pathways than their terrestrial counterparts, thus producing unique chemicals with a broad diversity and complexity. So far, more than 36,000 compounds have been isolated from marine micro- and macro-organisms including but not limited to fungi, bacteria, microalgae, macroalgae, sponges, corals, mollusks and tunicates, with hundreds of new marine natural products (MNPs) being discovered every year. Marine-based pharmaceuticals have started to impact modern pharmacology and different anti-cancer drugs derived from marine compounds have been approved for clinical use, such as: cytarabine, vidarabine, nelarabine (prodrug of ara-G), fludarabine phosphate (pro-drug of ara-A), trabectedin, eribulin mesylate, brentuximab vedotin, polatuzumab vedotin, enfortumab vedotin, belantamab mafodotin, plitidepsin, and lurbinectedin. This review focuses on the bioactive molecules derived from the marine environment with anticancer activity, discussing their families, origin, structural features and therapeutic use. Full article
Show Figures

Figure 1

Back to TopTop